Skip to main content
Aaron Rapoport, MD, Hematology, Baltimore, MD

AaronPaulRapoportMD

Hematology Baltimore, MD

Professor of Medicine, University MD School of Medicine

Overview of Dr. Rapoport

Dr. Aaron Rapoport is a hematologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Harvard Medical School and has been in practice 31 years. Dr. Rapoport accepts several types of health insurance, listed below. He is one of 12 doctors at University of Maryland Medical Center who specialize in Hematology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Rochester
    University of RochesterFellowship, Hematology and Medical Oncology, 1989 - 1993
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1986 - 1989
  • Harvard Medical School
    Harvard Medical SchoolClass of 1986

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1993 - Present
  • MD State Medical License
    MD State Medical License 1997 - 2025
  • NY State Medical License
    NY State Medical License 1987 - 1998
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
  • America's Top Doctors Castle Connolly, 2012-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...  
    Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Lectures

  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • University of Maryland Greenebaum Comprehensive Cancer Center Offers Novel Next-Generation CAR T-cell Therapy for B-cell Lymphomas in First-in-Human Clinical Trial
    University of Maryland Greenebaum Comprehensive Cancer Center Offers Novel Next-Generation CAR T-cell Therapy for B-cell Lymphomas in First-in-Human Clinical TrialNovember 25th, 2024
  • Maryland Governor's Cancer in Remission; Treatment Continues
    Maryland Governor's Cancer in Remission; Treatment ContinuesNovember 17th, 2015
  • Immunotherapy Is the Future of Cancer Research: 70% of Multiple Myeloma Patients Find Recovery with New Treatment
    Immunotherapy Is the Future of Cancer Research: 70% of Multiple Myeloma Patients Find Recovery with New TreatmentJuly 20th, 2015
  • Join now to see all

Grant Support

  • Immunotherapy After ASCT For MM Using Htert Vaccination + Vaccine-Primed T CellsNational Cancer Institute2007–2009
  • Immune Responses To T-Cell Expansion + PCV ImmunizationNational Cancer Institute2004–2005

Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    CareFirst BlueChoice Advantage
    CareFirst BlueChoice Network POS
    CareFirst BluePreferred PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Great West PPO
    Health Alliance PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    WEA Trust Preferred Provider Plan - Trust Pref
  • Please verify your coverage with the provider's office directly when scheduling an appointment